Bank of New York Mellon’s Biostage, Inc. Common Stock BSTG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-58,036
| Closed | -$19K | – | 4472 |
|
|
2017
Q3 | $19K | Buy |
58,036
+9,689
| +20% | +$3.88K | ﹤0.01% | 4219 |
|
|
2017
Q2 | $20K | Buy |
48,347
+18,601
| +63% | +$5.91K | ﹤0.01% | 4233 |
|
|
2017
Q1 | $11K | Buy |
29,746
+14,904
| +100% | +$8.16K | ﹤0.01% | 4255 |
|
|
2016
Q4 | $14K | Buy |
14,842
+204
| +1% | +$182 | ﹤0.01% | 4236 |
|
|
2016
Q3 | $16K | Sell |
14,638
-1,596
| -10% | -$1.72K | ﹤0.01% | 4233 |
|
|
2016
Q2 | $19K | Hold |
16,234
| – | – | ﹤0.01% | 4269 |
|
|
2016
Q1 | $29K | Hold |
16,234
| – | – | ﹤0.01% | 4148 |
|
|
2015
Q4 | $35K | Hold |
16,234
| – | – | ﹤0.01% | 4230 |
|
|
2015
Q3 | $13K | Hold |
16,234
| – | – | ﹤0.01% | 4345 |
|
|
2015
Q2 | $24K | Buy |
16,234
+966
| +6% | +$2.37K | ﹤0.01% | 4212 |
|
|
2015
Q1 | $50K | Hold |
15,268
| – | – | ﹤0.01% | 4140 |
|
|
2014
Q4 | $49K | Hold |
15,268
| – | – | ﹤0.01% | 4149 |
|
|
2014
Q3 | $124K | Hold |
15,268
| – | – | ﹤0.01% | 3996 |
|
|
2014
Q2 | $160K | Sell |
15,268
-19,148
| -56% | -$163K | ﹤0.01% | 3893 |
|
|
2014
Q1 | $313K | Sell |
34,416
-3,173
| -8% | -$18.8K | ﹤0.01% | 3730 |
|
|
2013
Q4 | $179K | Buy |
+37,589
| New | +$176K | ﹤0.01% | 3880 |
|
Bank of New York Mellon's BSTG Position: Q4 2017 in Review
Bank of New York Mellon sold out of Biostage, Inc. Common Stock (BSTG) in Q4 2017, closing a stake of 58,036 shares — an estimated $19K sold.
Bank of New York Mellon first reported a position in BSTG in Q4 2013 and held it in 16 quarters. The position peaked at $313K in Q1 2014. 0 funds tracked by Wall St. Rank hold BSTG as of Q4 2017.
- Bank of New York Mellon reported no remaining Biostage, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
- Bank of New York Mellon sold 58,036 Biostage, Inc. Common Stock shares in Q4 2017, an estimated $19K.
- Bank of New York Mellon first reported a position in Biostage, Inc. Common Stock in Q4 2013 and held it in 16 quarters.
- Bank of New York Mellon's Biostage, Inc. Common Stock position peaked at $313K in Q1 2014.
- 0 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q4 2017.
Based on Bank of New York Mellon's 13F filing for Q4 2017, filed 9 Feb 2018.